Momenta Pharmaceuticals (NASDAQ:MNTA) Lifted to “Buy” at BidaskClub

BidaskClub upgraded shares of Momenta Pharmaceuticals (NASDAQ:MNTA) from a hold rating to a buy rating in a report released on Thursday morning, BidAskClub reports.

A number of other equities research analysts have also recently commented on MNTA. Zacks Investment Research cut Momenta Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, May 9th. Cantor Fitzgerald set a $16.00 target price on Momenta Pharmaceuticals and gave the company a hold rating in a research report on Thursday, May 2nd. Finally, ValuEngine raised Momenta Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $22.23.

Shares of Momenta Pharmaceuticals stock opened at $12.02 on Thursday. Momenta Pharmaceuticals has a 52 week low of $9.51 and a 52 week high of $29.30. The stock has a 50 day moving average price of $11.25 and a two-hundred day moving average price of $12.85.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings data on Friday, August 2nd. The biotechnology company reported ($1.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.74). Momenta Pharmaceuticals had a negative net margin of 324.41% and a negative return on equity of 55.24%. The firm had revenue of $5.18 million during the quarter, compared to analyst estimates of $9.20 million. During the same period last year, the business posted ($0.91) EPS. The company’s revenue was down 60.2% on a year-over-year basis. As a group, research analysts predict that Momenta Pharmaceuticals will post -2.5 EPS for the current year.

In other Momenta Pharmaceuticals news, insider Anthony M. Manning sold 39,433 shares of the business’s stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $13.00, for a total value of $512,629.00. Following the transaction, the insider now owns 6,980 shares of the company’s stock, valued at $90,740. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Craig A. Wheeler sold 2,601 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $11.72, for a total value of $30,483.72. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 45,176 shares of company stock worth $580,013. 3.40% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of MNTA. Quantamental Technologies LLC bought a new stake in shares of Momenta Pharmaceuticals in the first quarter valued at $68,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Momenta Pharmaceuticals by 68.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,625 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 3,088 shares during the period. Marshall Wace North America L.P. bought a new stake in shares of Momenta Pharmaceuticals in the first quarter valued at $130,000. Algert Global LLC bought a new stake in shares of Momenta Pharmaceuticals in the second quarter valued at $143,000. Finally, Bank of Montreal Can raised its stake in shares of Momenta Pharmaceuticals by 298.3% in the second quarter. Bank of Montreal Can now owns 11,771 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 8,816 shares during the period. Hedge funds and other institutional investors own 99.88% of the company’s stock.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Further Reading: What are convertible shares? 

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.